

QUARTERLY REPORT 2018



Quantum Medical Transport, Inc.
Consolidated Balance Sheet
As of March 31, 2018

	Total
ASSETS	
Current Assets	
Bank Accounts	
BBVA Compass Checking	2,045.61
Checking Account	12,939.01
Savings Account	11,758.69
Savings II	25.35
Total Bank Accounts	\$26,768.66
Accounts Receivable	
AR - Wheelchair	42,476.40
Billing	0
Contractual Adj - Ambulance	0
Total Accounts Receivable	\$42,476.40
Other Current Assets	
Total Other Current Assets	\$0.00
Total Current Assets	\$69,245.06
Fixed Assets	
Ambulance	38,213.67
Office Improvements	28,250.00
Wheel Chair Van	49,175.00
Total Fixed Assets	\$115,638.67
Other Assets	
Line of Credit Advance	47,196.71
Accumulated Depreciation	-80,075.00
Goodwill	1,200,000.00
Total Other Assets	\$1,167,121.71
TOTAL ASSETS	\$1,421,250.50
LIABILITIES AND EQUITY	
Liabilities	
Current Liabilities	
Accounts Payable	
Accounts Payable	39,000.00
Total Accounts Payable	\$39,000.00
Other Current Liabilities	
Direct Deposit Liabilities	882.64

Direct Deposit Payable	0
Short Term Loan	16,124.09
Notes to Related Parties	29,400.00
Notes Payable	1,061,000.00
Payroll Liabilities	971.69
Euresti0599192191	-195.69
Euresti2015EM505570	-224.77
Federal Taxes (941/944)	0.00
Federal Unemployment (940)	1158.17
Schiwart 0013036186140445	-384.46
TX Unemployment Tax	1288.72
Total Payroll Liabilities	\$2,661.18
Total Other Current Liabilities	\$1,149,067.91
Total Current Liabilities	\$1,149,067.91
Equity	
Stockholders Deficit	
Series A Preferred Stock, \$0.000001 par value, 10,000,000 shares authorized; none issued and outstanding	
Series B Preferred Stock, \$0.000001 par value, 10,000 shares authorized; none issued and outstanding	
Common Stock, \$0.000001 par value, 10,000,000,000 shares authorized; 8,145,898,915 shares issued and O/S	8,146.00
Additional Paid in capital	
Accumulated deficit	264,036.59
Total Stockholders' Deficit	272,182.59
TOTAL LIABILITIES AND EQUITY	\$1,421,250.50

Quantum Medical Transport, Inc.
Profit and Loss
(Unaudited)
Consolidated for the Period Ending March 31, 2018

	<u>2018</u>
Revenue	<u>280,769</u>
OPERATING EXPENSES	
COGS	<u>30,478</u>
G&A	<u>245,382</u>
TOTAL EXPENSES	<u>275,860</u>
NET OPERATING INCOME (LOSS)	<u>\$4,909.00</u>

Quantum Medical Transport, Inc.
Statement of Cash Flows
(Unaudited)
Ending March 31, 2018

	Total
CASH FLOW FROM OPERATING ACTIVITIES	
Net Income	\$ 4,909.00
Net Cash Provided by Operating activities	\$ 4,909.00
CASH FLOW FROM FINANCING ACTIVITIES	
Net Cash Provided by investing activities (ICO)	\$ 10,000
CASH FLOW FROM FINANCING ACTIVITIES	
Equity (common shares)	0.00
Line of Credit	\$ 47,196.71
Borrowing on related party debt	0.00
Net Cash Provided by Financing activities	\$ 47,196.71
NET INCREASE IN CASH	-5,731.34
CASH AT BEGINNING OF PERIOD	32,530.00
CASH AT END OF PERIOD	\$26,768.66

NOTES TO FINANCIAL STATEMENTS
(Unaudited)

NOTE 1 – BASIS OF PRESENTATION

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America.

In the opinion of management, the accompanying financial statements contain all adjustments, consisting only of normal recurring accruals, necessary for a fair presentation of the Company's financial position as of March 31, 2018 and the results of its operations and cash flows as of March 31, 2018.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

CASH AND CASH EQUIVALENTS

The Company considers all highly liquid investment purchased with an original maturity of three months or less to be cash equivalents. No cash equivalent as of March 31, 2018.

REVENUE RECOGNITION

The Company considers revenue recognizable when persuasive evidence of an arrangement exists, the price is fixed or determinable, goods or services have been delivered, and collectability is reasonable assured. The company recognized operating revenue of \$280,769.88 as of March 31, 2018 compared to \$9,500.00 same period last year.

USE OF ESTIMATES

The preparation of the Company's financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates.

FAIR VALUE MEASUREMENT

The Company adopted FASB ASC 820-Fair Value Measurements and Disclosures, or ASC 820, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company's financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

The Company did not have any Level 2 or Level 3 assets or liabilities as of June 30, 2017.

Cash is considered to be highly liquid and easily tradable as of June 30, 2017 and therefore classified as Level 1 within our fair value hierarchy.

In addition, FASB ASC 825-10-25 Fair Value Option, or ASC 825-10-25, was effective for January 1, 2008. ASC 825-10-25 expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.

INCOME TAXES

The Company uses the asset and liability method of accounting for income taxes, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of certain assets and liabilities. Deferred income tax assets and liabilities are computed annually for the difference between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period, plus or minus the change during the period in deferred tax assets and liabilities.

Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of the assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company had no significant deferred tax items arise during any of the periods presented.

CONCENTRATION OF CREDIT RISK

The Company does not have any concentration of related financial credit risk.

RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not expect the adoption of any recent accounting pronouncements to have a material impact on its financial statements.

NOTE 3 – GOING CONCERN

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The company has sufficient revenue and assets to continue as a going concern. As shown in the accompanying financial statements, the Company had accumulated deficit of \$264,036.59 for the period as of March 31, 2018. The company recognized \$280,769.88 revenue for the period ended March 31, 2018. As of March 31, 2018 the company had consolidated assets of consisting of \$30,469 wheel chair receivables, \$110,000

insurance claims receivables, \$115,638 fixed assets, \$26,768 Cash in bank, and \$1,200,000 in Goodwill. The company owns 4-ambulances and 7-wheel chair lift vans. Management values the company's goodwill at \$1.2 Million based upon 1x revenue including intangibles such as long term contracts and receivables.

Note 4 – Related Party

The amount of notes payable owed to Ricky Bernard is \$29,400 as of March 31, 2018. The company paid \$40,000 deposit for its merger, which was financed by third party debt on behalf of Ricky Bernard, to cover the expense of the merger agreement between Quantum Medical Holdings, Inc. and Quantum Medical Transport, Inc. formerly A Clean Slate, Inc. (DRWN).

Note 5 – Commission on acquisition

No commission was paid to any party.

Note 6 – Equity

The company had authorized shares 10,000,000,000 a/o March 31, 2018. We had outstanding common shares of 8,145,898,915. The company had 5,841,642,932 restricted shares of which 4.7 Billion are held by the founder Ricky Bernard. The public float consisted of 2,194,255,983 common shares. The company recently repurchased 110 Million common shares from shareholder and retired the shares to the treasury. The company issued 375 Million restricted common shares to a vendor in lieu of cash. The company issued 100 Million shares to Northbridge Financial as part of their debt conversion rights. The company entered into a settlement agreement with Northbridge Financial to restructure the company debt through a 3(a)10 lawsuit that was filed by Northbridge, in which Northbridge received stock in exchange for the debt. The \$810,000 debt was incurred as a result of the acquisition of United Ambulance, LLC. The company mutually terminated its 3(a)10 settlement agreement with Northbridge Financial and entered into a settlement with CF3 Enterprises, LLC a New York private equity firm that acquired the company's total outstanding debt of \$1,455,000 through a 3(a)10 settlement. CF3 Enterprises has subsequently released \$700,000 of debt back to Northbridge Financial which requires

Northbridge Financial to file a new 3(a)10 settlement agreement with the court and make payment to the company vendors as agreed.

The company is obligated under the 3(a)10 to issue shares in settlement of the debt and to increase the authorized shares as required under a share reserve agreement.

Note 7 – Subsequent Events

N/A

Item 1A. Risk Factors

The primary risk associated with our ongoing operations is that we could become subject to future legal actions depending upon State and Federal Regulatory bodies regarding Emergency and Non-Medical Emergency Transportation (NMET) industry. We are subject to Medicare/Medicaid audits and we are regulated as a licensed ambulance service by the State of Texas. We transport patients and could be subject to litigation involving vehicle accidents and or physical bodily injury, medical negligence with patients being transported by our employees. There could be a decline in need for our services which could impact our future earnings. We are embarking upon a new technology project in blockchain technology and offering a Token/Coin through an ICO (Initial Coin Offering) which opens us up to significant legal risk with legal regulation to be introduced by the SEC, and FINRA and other governmental agencies could deem such offerings illegal. While we are relying upon Reg D Rule 506 (c) for our private placement offering, we may still be subject to litigation by governmental regulatory agencies. Investors in our tokens/coins may not have a market for liquidity as a secondary market may not develop and their initial investment may be lost.

Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

This section of the financials includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this prospectus.

These forward-looking states are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or out predictions.

PLAN OF OPERATION

We currently operate in Houston, and San Antonio, Texas and its surrounding counties throughout the State of Texas providing emergency ambulance and non-emergency medical transportation services to patients in need of transport to hospital, doctors offices and dialysis (NMET). We have embarked upon new growth opportunities in the blockchain technology space as user friendly medical records data storage and transport provider. We see this as a subscription service provider in which our current customers and other medical professionals within our marketplace can utilize our encrypted blockchain data technology to interface with patients, shares records and data between providers and insurers. We will be bringing on experts in blockchain open source code participants as partners and operators to develop this technology for product launch. Our mission is to improve quality of care through getting real time patient information to healthcare professionals in a safe, secure HIPPA compliant manner, thus saving time and reducing the overall cost of healthcare.

We are on a path to raising \$50 Million via private placement Initial Coin Offering in which we will develop the technological platform for this subscription service. We released a technical paper describing the functionality of the project. The use of proceeds from the ICO will be to develop and launch the project, debt consolidation, acquisition of local competitors in the emergency and non-emergency medical space and share repurchase of up to 20% of the common share in the public market. If successful the token raise should allow for significant capital to meet our growth initiatives. We would buy down the 3(a)10 debt from Northbridge Financial and CF3 Enterprises.

Liquidity and Capital

We had \$280,000 operating revenue for the period. We had cash on hand \$26,768. We have two lines of credit a \$75,000 LOC with Factor King and \$12,000 LOC with Fundbox. The company has sufficient liquidity and working capital to continue operations as a going concern.

Resources Assets and Liabilities

The company recognized \$280,769 revenue for the period ended March 31, 2018. As of March 31, 2018 the company had consolidated assets of consisting of \$30,469 wheel chair receivables, \$220,000 insurance claims receivables, \$115,638 fixed assets, \$26,768 Cash in bank, and \$1,200,000 in Goodwill. The company owns 4-ambulances and 7-wheel chair lift vans. Management values the company's goodwill at \$1.2 Million based upon 1times revenue including intangibles such as long term contracts and receivables.

Off-Balance Sheet Arrangements

We are not currently a party to, or otherwise involved with, any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3. Quantitative and Qualitative Disclosure about Market Risk

Not applicable.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures and determined that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report. The evaluation considered the procedures designed to ensure that the information required to be disclosed by us in reports filed or submitted under the OTC Markets Rules is recorded, processed, summarized and reported within the time periods specified in the OTC Markets rules and forms and communicated to our management as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control over Financial Reporting

During the period covered by this Quarterly Report, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

(c) Inherent Limitations of Disclosure Controls and Internal Controls over Financial Reporting

Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation or effectiveness to future periods are subject to risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Part II

OTHER INFORMATION

Item 1. Legal Proceedings

The company entered into a settlement agreement with Northbridge Financial to restructure the company debt through a 3(a)10 lawsuit that was filed by Northbridge, in which Northbridge received stock in exchange for the debt. The \$810,000 debt was incurred as a result of the acquisition of United Ambulance, LLC. The company mutually terminated its 3(a)10 settlement agreement with Northbridge Financial and entered into a settlement with CF3 Enterprises, LLC a New York private equity firm that acquired the company's total outstanding debt of \$1,455,000 through a 3(a)10 settlement. CF3 Enterprises has subsequently released \$700,000 of debt back to Northbridge Financial which requires Northbridge Financial to file a new 3(a)10 settlement agreement with the court and make payment to the company vendors as agreed.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities

Not Applicable.

Item 4. Subsequent Events

None.

Item 5.

Other Information

Not applicable.

SIGNATURES

In accordance with the requirements of the OTC Markets, the issuer caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Quantum Medical Transport, Inc.

Dated March 31, 2018

/s/ Ricky Bernard

Ricky Bernard, President, Director and Chief Executive Officer

[This page is intentionally blank]